FGFR3 and chronic myelogenous leukemia, BCR-ABL1 positive: Traer et al. suggested that reactivation of the MAPK pathway by FGFR3 accounts for FGF-mediated resistance of BCR-ABL1-rearranged chronic myeloid leukemia cells to imatinib.